Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT02356653
EARLY_PHASE1

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Sponsor: Children's Hospital of Philadelphia

View on ClinicalTrials.gov

Summary

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.

Official title: Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells

Key Details

Gender

All

Age Range

Any - 30 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2013-12

Completion Date

2030-01

Last Updated

2026-02-20

Healthy Volunteers

No

Interventions

BIOLOGICAL

Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)

Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.

Locations (1)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States